HRP20151344T1 - Kristalni oblik slobodne baze bifenilnog spoja - Google Patents

Kristalni oblik slobodne baze bifenilnog spoja Download PDF

Info

Publication number
HRP20151344T1
HRP20151344T1 HRP20151344TT HRP20151344T HRP20151344T1 HR P20151344 T1 HRP20151344 T1 HR P20151344T1 HR P20151344T T HRP20151344T T HR P20151344TT HR P20151344 T HRP20151344 T HR P20151344T HR P20151344 T1 HRP20151344 T1 HR P20151344T1
Authority
HR
Croatia
Prior art keywords
compound according
ester
crystalline
biphenyl
preparation
Prior art date
Application number
HRP20151344TT
Other languages
English (en)
Croatian (hr)
Inventor
Grahame Woollam
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562758&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20151344(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of HRP20151344T1 publication Critical patent/HRP20151344T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
HRP20151344TT 2009-07-15 2010-07-14 Kristalni oblik slobodne baze bifenilnog spoja HRP20151344T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22580309P 2009-07-15 2009-07-15
PCT/US2010/041903 WO2011008809A1 (en) 2009-07-15 2010-07-14 Crystalline freebase forms of a biphenyl compound
EP10732616.7A EP2453894B1 (en) 2009-07-15 2010-07-14 Crystalline freebase form of a biphenyl compound

Publications (1)

Publication Number Publication Date
HRP20151344T1 true HRP20151344T1 (hr) 2016-01-01

Family

ID=42562758

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151344TT HRP20151344T1 (hr) 2009-07-15 2010-07-14 Kristalni oblik slobodne baze bifenilnog spoja

Country Status (20)

Country Link
US (12) US8541451B2 (enExample)
EP (2) EP2987490B1 (enExample)
JP (4) JP5651174B2 (enExample)
KR (1) KR101742252B1 (enExample)
CN (1) CN102470130B (enExample)
AU (1) AU2010273514B2 (enExample)
BR (1) BR112012000890A2 (enExample)
CA (2) CA2765621C (enExample)
DK (1) DK2453894T3 (enExample)
ES (2) ES2557553T3 (enExample)
HR (1) HRP20151344T1 (enExample)
HU (1) HUE026414T2 (enExample)
IL (1) IL216995A (enExample)
MX (1) MX2012000682A (enExample)
PL (2) PL2987490T3 (enExample)
PT (1) PT2453894E (enExample)
SG (2) SG178036A1 (enExample)
SI (1) SI2453894T1 (enExample)
SM (1) SMT201600019B (enExample)
WO (1) WO2011008809A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
ES2557553T3 (es) 2009-07-15 2016-01-27 Theravance Biopharma R&D Ip, Llc Forma de base libre cristalina de un compuesto de bifenilo
RS54201B1 (sr) 2010-07-13 2015-12-31 Theravance Biopharma R&D Ip, Llc Postupak za pripremu bifenil-2-ilkarbaminske kiseline
HUE054212T2 (hu) * 2013-02-21 2021-08-30 Pfizer Szelektív CDK4/6 inhibitor szilárd formái
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
CN112694434B (zh) * 2020-12-29 2023-06-16 浙江和泽医药科技股份有限公司 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法
CN118401497A (zh) 2021-12-09 2024-07-26 医药化学公司 雷芬那辛的结晶型丙酮溶剂化物
CN114276290B (zh) * 2021-12-24 2024-05-28 浙江和泽医药科技股份有限公司 一种雷芬那辛无水晶型及其制备方法
CN117180235A (zh) * 2023-09-19 2023-12-08 山东京卫制药有限公司 一种无定型雷芬那辛吸入制剂
CN117263848A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛的吸入喷雾剂
CN117263849A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛三水合物晶型及其制备方法
US20250136550A1 (en) 2023-10-27 2025-05-01 Theravance Biopharma R&D Ip, Llc Processes for preparing revefenacin and compositions comprising the same
CN119775192B (zh) * 2024-12-31 2025-11-28 山东京卫制药有限公司 一种三苯乙酸雷芬那辛晶型及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2425983C3 (de) 1973-06-12 1978-09-14 Toyama Chemical Co. Ltd., Tokio Sulfonsäuresalze von Acylcholinen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
FI88112C (fi) 1985-07-30 1993-04-13 Glaxo Group Ltd Anordning foer administrering av laekemedel till patienter
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
ES2216800T3 (es) 1991-12-18 2004-11-01 Minnesota Mining And Manufacturing Company Formulaciones de aerosol en suspension.
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
CA2182568A1 (en) 1994-02-10 1995-08-17 Makoto Takeuchi Novel carbamate derivative and medicinal composition containing the same
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5637820A (en) * 1995-01-06 1997-06-10 Wittman; Kenneth L. Stringed instrument with on-board tuner
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
AU718263B2 (en) 1995-04-14 2000-04-13 Smithkline Beecham Corporation Metered dose inhaler for salmeterol
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6255303B1 (en) 1998-03-14 2001-07-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone PDE III/IV inhibitors
EA200000956A1 (ru) 1998-04-18 2001-04-23 Глаксо Груп Лимитед Фармацевтический аэрозольный препарат
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
EP1169019B1 (en) 1999-04-14 2003-02-26 Glaxo Group Limited Pharmaceutical aerosol formulation
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002070490A1 (en) 2001-03-08 2002-09-12 Glaxo Group Limited Agonists of beta-adrenoceptors
EP1370521B1 (en) 2001-03-22 2007-12-19 Glaxo Group Limited Formanilide derivatives as beta2-adrenoreceptor agonists
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
PL211953B1 (pl) 2001-09-14 2012-07-31 Glaxo Group Ltd Pochodna fenetanoloaminy, zawierający ją środek farmaceutyczny i zastosowanie pochodnej fenetanoloaminy
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
PE20050973A1 (es) 2003-10-29 2005-11-19 Theravance Inc Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TW200540154A (en) 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound
WO2006099166A1 (en) 2005-03-10 2006-09-21 Theravance, Inc. Crystalline forms of a biphenyl compound
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7465870B1 (en) * 2008-03-11 2008-12-16 Homan Randy W Illuminated heart-shaped guitar with strobe lights and a modified bridge
ES2557553T3 (es) 2009-07-15 2016-01-27 Theravance Biopharma R&D Ip, Llc Forma de base libre cristalina de un compuesto de bifenilo
RS54201B1 (sr) 2010-07-13 2015-12-31 Theravance Biopharma R&D Ip, Llc Postupak za pripremu bifenil-2-ilkarbaminske kiseline

Also Published As

Publication number Publication date
AU2010273514B2 (en) 2015-01-22
US20180186740A1 (en) 2018-07-05
KR101742252B1 (ko) 2017-05-31
US8541451B2 (en) 2013-09-24
SMT201600019B (it) 2016-02-25
PT2453894E (pt) 2016-02-02
JP2012533550A (ja) 2012-12-27
US11649209B2 (en) 2023-05-16
KR20130027004A (ko) 2013-03-14
US9226896B2 (en) 2016-01-05
HK1219415A1 (en) 2017-04-07
EP2987490B1 (en) 2017-06-14
US10100013B2 (en) 2018-10-16
US20160143897A1 (en) 2016-05-26
HUE026414T2 (hu) 2016-05-30
SG178036A1 (en) 2012-03-29
CA2989129A1 (en) 2011-01-20
EP2987490A1 (en) 2016-02-24
US8921396B2 (en) 2014-12-30
US11691948B2 (en) 2023-07-04
JP2016026214A (ja) 2016-02-12
JP2015003929A (ja) 2015-01-08
PL2453894T3 (pl) 2016-04-29
SI2453894T1 (sl) 2016-02-29
WO2011008809A1 (en) 2011-01-20
JP6338505B2 (ja) 2018-06-06
MX2012000682A (es) 2012-02-28
US11858898B2 (en) 2024-01-02
US20220009890A1 (en) 2022-01-13
US9415041B2 (en) 2016-08-16
US9765028B2 (en) 2017-09-19
US20190248743A1 (en) 2019-08-15
US20230303492A1 (en) 2023-09-28
US20250179019A1 (en) 2025-06-05
BR112012000890A2 (pt) 2017-10-31
CN102470130A (zh) 2012-05-23
CA2989129C (en) 2021-03-09
CA2765621C (en) 2018-02-13
US20170081283A1 (en) 2017-03-23
JP5651174B2 (ja) 2015-01-07
IL216995A0 (en) 2012-02-29
ES2639642T3 (es) 2017-10-27
CN102470130B (zh) 2013-09-04
IL216995A (en) 2017-10-31
JP2017171692A (ja) 2017-09-28
ES2557553T3 (es) 2016-01-27
EP2453894A1 (en) 2012-05-23
SG10201407913UA (en) 2015-01-29
EP2453894B1 (en) 2015-11-04
US20220306580A1 (en) 2022-09-29
PL2987490T3 (pl) 2017-12-29
US20130338191A1 (en) 2013-12-19
DK2453894T3 (en) 2016-01-25
CA2765621A1 (en) 2011-01-20
US10550081B2 (en) 2020-02-04
US20110015163A1 (en) 2011-01-20
AU2010273514A1 (en) 2012-01-19
HK1168050A1 (zh) 2012-12-21
US11008289B2 (en) 2021-05-18
US20200308116A1 (en) 2020-10-01
US20150164796A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
HRP20151344T1 (hr) Kristalni oblik slobodne baze bifenilnog spoja
EP1797099B1 (en) Piperidinylamino-thieno[2,3-d] pyrimidine compounds
CN101255169B (zh) 普拉格雷盐及其制备方法
Cocco et al. Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties
KR102120883B1 (ko) 인간 히스톤 메틸트랜스퍼라제 ezh2 억제제의 염 형태
HRP20130192T1 (hr) Kristalni oblik bifenilnog spoja
JP2012533550A5 (enExample)
ME02066B (me) Kristalni oblici hidrohloridne soli ( 4a-r,9a-s)- 1-( 1h-benzoimidazol- s-karbonil)- 2,3,4,4a,9,9a-heksahidr0- 1h-inden0[2,1-b]piridin-6-karbonitrila i njihova upotreba kao inhibitora hsd 1
HRP20100035T1 (hr) Kristalni oblici bifenilnog spoja
EP3920915A1 (en) Methods and compositions for modulating splicing
TWI574687B (zh) 具有鋅結合部份之刺蝟拮抗劑
MX2011008858A (es) Compuestos de diarilhidantoina y diariltiohidantoina especificos.
CN106518841A (zh) 环己烷衍生物或其立体异构体或盐及其制备与应用
CN106795099A (zh) 用于治疗高血压和心血管疾病的新型前药和组合物
HRP20151338T1 (hr) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita
ZA200703596B (en) Thienopyridinone compounds and methods of treatment
JP2013541592A5 (enExample)
JP3927228B2 (ja) Nmda/nr2b拮抗物質としての3−フルオロ−ピペリジン
CN109280030B (zh) 苯骈氮杂烷基芳基哌嗪衍生物及在制备药物中的应用
CN101595099B (zh) 晶体盐酸度洛西汀
ME02480B (me) Optimizirana sinteza čistih, nepolimorfnih, kristalnih žučnih kiselina sa određenom veličinom čestica
CN103664793B (zh) 阿奇沙坦中间体及其制备方法
CN103664792B (zh) 阿奇沙坦中间体及其制备方法
SK141998A3 (en) Piperidines and pyrrolidines
JP6927548B2 (ja) ある種のタンパク質キナーゼ阻害剤